For years, U.S. scientists and biotech companies have watched warily as China has made strides onto the global stage, overtaking them in research spending, patent applications, and clinical trials. To many observers, it has been a sign that the U.S. needs to urgently modernize a lumbering clinical trial and regulatory system. But now, a key…
First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them. You can submit a…
HONG KONG, CHINA: Hong Kong has emerged as a major biotech fundraising hub, attracting dozens of Chinese biotech firms to list in the city. Cheng Xin | Getty Images News | Getty Images For years, Chinese companies such as Alibaba and Baidu headed to the U.S. to list their shares, citing its deeper capital markets…
I spent nearly two decades covering the biotech and pharma sector, first in Washington, D.C., and then in Beijing. My first story, published in 2007, covered the U.S. Food and Drug Administration’s decision to open its inaugural overseas office in China, a fast-emerging market I later covered for 12 years. In that time, I saw…
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01. Should the federal government try to slow — or even block — U.S. biotech deals that could benefit China? The question of…
Hong Kong IPOs 2025: Market views, mega deals, emerging trends Hong Kong cemented its status as the world’s leading initial public offerings venue in 2025, marking a year of momentum, progress and transformation. By mid-December, the market had raised HKD274.6 billion (USD35.2 billion) from 106 new listings, with four of the world’s top 10 IPOs…
Pharma giant AstraZeneca will list on the New York Stock Exchange on Monday, days after it announced big commitments on the other side of the world. Like the rest of Big Pharma, the company has a balancing act. It wants a close relationship with the U.S., its biggest market, and the listing is intended to…
China SXT Pharmaceuticals (NASDAQ: SXTC) announced an AI Insight Initiative to explore applying artificial intelligence and digital tools across its Traditional Chinese Medicine raw-material supply chain. The company plans to evaluate AI-supported methods for cultivation environment monitoring, origin and authenticity assessment, quality evaluation and grading, and supply-demand forecasting and circulation efficiency. The stated…
It was another month of gains for the stock market, even as Wall Street had to navigate a barrage of uncertainty. Since the Investing Club’s last Monthly Meeting on Oct. 7, the S & P 500 jumped 2%. October marked the sixth month in a row of gains, despite the longest-ever government shutdown and valuation…
WASHINGTON — AstraZeneca is set to strike a deal with the Trump administration to lower drug prices, people familiar with the matter told STAT. More details are expected to be shared at a 5 p.m. announcement with President Trump in the Oval Office. It comes a day after the company said it would invest $4.5…